Sirion Therapeutics (drug rights)
M&A
STATUS
Asset Purch.
LATEST DEAL TYPE
1
FINANCING ROUNDS
Description
United States rights for DUREZOL and emulsion and global rights for ZYCLORIN. DUREZOL emulsion is a topical ophthalmic corticosteroid used to treat postoperative inflammation and pain associated with ocular surgery. ZYCLORIN is a topical ophthalmic immunomodulator and immunosuppressive agent.
Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Other Business Products and Services
Acquirer
Primary Office
- 3110 Cherry Palm Drive
- Suite 340
- Tampa, FL 33619
- United States
Sirion Therapeutics (drug rights) Valuation and Funding
| Deal Type | Date | Amount | Post-Val | Valuation/ EBITDA |
Debt | Status |
|---|
This information is reserved for PitchBook Platform users. To explore Sirion Therapeutics (drug rights)‘s full profile, request access.
Request full access to PitchBookSirion Therapeutics (drug rights) Former Investors
| Investor Name | Investor Type | Holding | Participating Rounds | Investor Since | Board Seat | Contact Info |
|---|
This information is reserved for PitchBook Platform users. To explore Sirion Therapeutics (drug rights)‘s full profile, request access.
Request full access to PitchBook